Core Viewpoint - Tempus AI stock is currently in a bear market, having experienced a significant decline of 36% from its peak in September of the previous year [1] Group 1: Stock Performance - The stock price has fallen to $66, indicating a substantial drop from its previous highs [1] - The market capitalization of Tempus AI has decreased from $17.8 billion in October [1]

Core Insights - Tempus AI reported preliminary unaudited financial results for the fourth quarter and full year ending December 31, 2025, with total revenue of approximately $1.27 billion, representing a year-over-year growth of about 83% [1] - The company's diagnostic business revenue reached approximately $955 million, a year-over-year increase of about 111%, driven by a 26% increase in tumor testing volume and a 29% increase in genetic testing volume [1] - The data and applications segment generated revenue of $316 million, reflecting a year-over-year growth of about 31%, primarily due to a 38% increase in Insights business [1] Revenue Breakdown - For Q4 2025, Tempus AI reported revenue of approximately $367 million, a year-over-year increase of about 83% [1] - Diagnostic business revenue for Q4 was approximately $266 million, showing a year-over-year growth of about 121%, driven by a 29% increase in tumor testing volume and a 23% increase in genetic testing volume [1] - Data and applications revenue for Q4 was approximately $100 million, with a year-over-year growth of about 25%, and Insights business growth of approximately 68% when excluding the impact of AstraZeneca warrants from Q4 2024 [1] Strategic Outlook - CEO Eric Lefkofsky highlighted that 2025 was an exceptional year for Tempus, with both product lines exceeding initial expectations [2] - The genomic (tumor) product testing volume has accelerated for three consecutive quarters, achieving the highest unit growth rate in years [2] - The company anticipates a strong entry into 2026, with accelerating growth in both main business segments and the inherent financial leverage of its platform being released [2]

Market Overview - U.S. stock futures declined on Monday following a positive close on Friday, with major benchmark indices trading lower [1] - The Dow Jones, S&P 500, and Nasdaq 100 experienced declines of 0.78%, 0.76%, and 1.04% respectively in premarket trading [4] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations of 60,000 and down from November's revised gain of 56,000 [2] - The 10-year Treasury bond yielded 4.19%, while the two-year bond was at 3.53%, with a 95% likelihood of the Federal Reserve keeping interest rates unchanged in January [3] Company Performance - Vistra Corp. (NYSE:VST) rose 0.69% after signing a 20-year nuclear power deal with Meta Platforms Inc. (NASDAQ:META) [7] - Alibaba Group Holding Ltd. (NYSE:BABA) increased by 4.44% as its Cloud's Qwen series became the most widely used open-source AI system, surpassing 700 million downloads [7] - Tempus AI Inc. (NASDAQ:TEM) jumped 8.12% after reporting a record $1.1 billion in total contract value and approximately 126% net revenue retention for 2025 [7] - Xpeng Inc. (NYSE:XPEV) gained 2.75% after unveiling its global 2026 P7+ flagship and reporting 126% delivery growth in 2025 [14] - Boot Barn Holdings Inc. (NYSE:BOOT) saw a slight decline of 0.37% despite reporting preliminary third-quarter net sales of $705.6 million, a 16.0% increase over the prior year [14] Sector Performance - Materials, utilities, and consumer discretionary stocks posted the largest gains on Friday, while health care and financial shares closed lower [9] - For the week, the S&P 500 rose 1%, with the Dow and Nasdaq increasing by 2.3% and 1.9% respectively [9] Upcoming Economic Data - Key economic data releases include December's NFIB optimism index, CPI data, and U.S. budget deficit, with several Federal Reserve officials scheduled to speak throughout the week [13][16]

Core Insights - Tempus AI, Inc. has achieved a record Total Contract Value (TCV) exceeding $1.1 billion as of December 31, 2025 [1] - The company signed data agreements with over 70 customers in 2025, including major pharmaceutical companies [1] Company Overview - Tempus AI, Inc. is a technology company focused on advancing precision medicine through the adoption of artificial intelligence [1] - The company operates in the healthcare technology sector, specifically targeting the pharmaceutical industry [1] Customer Engagement - The customer base includes both large and mid-sized pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, and Boehringer Ingelheim [1] - The agreements signed in 2025 reflect a strong demand for Tempus's AI-driven solutions in the pharmaceutical sector [1]

"2025 was an exceptional year for Tempus with the strength of both of our product lines exceeding our initial expectations for the year,†said Eric Lefkofsky, Founder and CEO of Tempus. "Within Diagnostics, year- over-year volume growth of our genomics (oncology) offering accelerated for the third consecutive quarter hitting the highest unit growth rate we have seen in years. Our Data and Application business is performing even better with record revenue of ~$100 million in the fourth quarter, achieving full ...

Core Insights - Tempus AI (TEM) has experienced significant growth, with shares increasing by 82.4% over the past year, outperforming the industry growth of 2.6% and the S&P 500's 19.3% increase [1][10] Company Performance - Tempus has achieved profitability on a non-GAAP basis and is focusing on disciplined expansion and long-term growth, with a portfolio that includes oncology therapy selection, hereditary testing, and minimal residual disease (MRD) [2] - The company reported a positive adjusted EBITDA of $1.5 million in the third quarter, marking a significant milestone after a decade of efforts [7] Revenue Segments - The Genomics segment has seen revenues more than double year-over-year, driven by increased oncology testing volumes and the integration of Ambry hereditary testing, with total genomics testing volumes rising by 33% [4][10] - The Data & Services segment has emerged as a high-margin revenue stream, with revenues growing by 26.1% year-over-year, primarily due to data licensing [6] Regulatory Developments - In September 2025, Tempus received FDA 510(k) clearance for its xR IVD to support drug development programs and launched a new liquid biopsy assay for treatment response monitoring [5] Market Outlook - The Zacks Consensus Estimate projects a 59.5% improvement in loss per share for 2025 and a 71.6% improvement for 2026, with revenues expected to grow by 82.3% to $1.26 billion in 2025 and reach $1.56 billion in 2026 [11]

Core Insights - Tempus AI, Inc. is advancing the adoption of AI in precision medicine, particularly in gastrointestinal cancers [1] Group 1: Company Developments - Eight abstracts from Tempus have been accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium [1] - The symposium is scheduled to take place from January 8 to 10 in San Francisco, California [1] Group 2: Research Commitment - The research presented by Tempus at the ASCO GI symposium reflects the company's commitment to advancing progress in gastrointestinal cancers [1] - The presentations demonstrate the effectiveness of utilizing AI in cancer research [1]

Core Insights - Rune Labs has appointed Amy Gordon Franzen as the new Chief Executive Officer to lead the company's growth, particularly in expanding its AI platform StrivePD for neurological conditions beyond Parkinson's Disease [1][4] - The company aims to enhance its partnerships with clinicians, payers, and biopharma leaders to improve patient care and expand its commercial reach [3][5] Company Overview - Rune Labs specializes in precision medicine for neurology, utilizing advanced AI and FDA-cleared algorithms to support care delivery and therapy development [5] - The StrivePD platform, launched in 2022, has evolved into a comprehensive software ecosystem that facilitates remote care, AI-enabled symptom tracking, and real-world evidence generation for Parkinson's patients [3][5] Leadership Background - Amy Franzen previously held significant roles at Tempus, Groupon, Nike, and McKinsey & Company, where she focused on building partnerships and scaling clinical trial organizations [2] - Co-founder Brian Pepin will transition to President, Biopharma and Platform, to lead the expansion of Rune Labs' biopharma partnerships and research portfolio [1][3] Strategic Goals - The company plans to extend its AI-enabled care infrastructure to address a broader range of neurological conditions, including Alzheimer's disease and other forms of dementia [1][3] - Franzen emphasized the importance of scaling the commercial and clinical infrastructure to integrate more deeply with trial sponsors, payers, and health systems [5]

Key Takeaways TEM ended Q3 2025 with $760M cash, no current debt, and manageable leverage backing a stable balance sheet. TEM reached a positive adjusted EBITDA of $1.5M, marking an inflection point as revenues scale. TEM carries $1.25B in long-term debt, while its cash strength supports AI investment and data expansion. At the end of the third quarter of 2025, Tempus AI (TEM) reported a stable and well-capitalized balance sheet, reflecting prudent financial management and a strengthening operating profile. ...

Group 1: Ark Invest's Strategic Trades - Ark Invest made significant trades focusing on Tempus AI Inc. and Kodiak AI Inc., indicating a strategic interest in the AI sector [1] - The firm also executed notable transactions involving Roku Inc. and Shopify Inc. [1] Group 2: Tempus AI Trade - Ark Invest purchased 32,627 shares of Tempus AI through the ARK Genomic Revolution ETF and 195,999 shares via the ARK Innovation ETF, totaling approximately $14.8 million at a closing price of $64.70 [2] - There is a surge in interest in Tempus AI, reflecting bullish sentiment in the market [3] Group 3: Kodiak AI Trade - Ark Invest added 53,302 shares of Kodiak AI to its ARK Autonomous Technology & Robotics ETF, valued at approximately $554,340 with a closing price of $10.40 [4] - Kodiak AI is a key player in the driverless truck industry, aligning with Ark's focus on innovative technologies [4] Group 4: Roku Trade - Ark Invest sold 109,254 shares of Roku from ARKK, valued at approximately $12.5 million with a closing price of $114.68 [5] - Roku's third-quarter earnings report showed net revenue of $1.211 billion, up 14% year over year, exceeding the Street consensus estimate [5] Group 5: Shopify Trade - Ark Invest reduced its stake in Shopify by selling 24,447 shares from ARKK, valued at approximately $4.06 million with a closing price of $166.21 [6] - Recent updates from Shopify, including the Winter 2026 Edition, have reinforced confidence in its long-term growth [7] Group 6: Other Key Trades - Ark Invest sold 3,558 shares of Natera Inc. and 7,228 shares of Guardant Health Inc. from ARKG, while buying 47,587 shares of Personalis Inc. for ARKG [9]